Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,909 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, Lambkin-Williams R, Smith P, Zhang Q, Beigelman L, Blatt LM, Fry J. DeVincenzo JP, et al. Among authors: smith p. N Engl J Med. 2015 Nov 19;373(21):2048-58. doi: 10.1056/NEJMoa1413275. N Engl J Med. 2015. PMID: 26580997 Free article. Clinical Trial.
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.
Patel K, Kirkpatrick CM, Nieforth KA, Chanda S, Zhang Q, McClure M, Fry J, Symons JA, Blatt LM, Beigelman L, DeVincenzo JP, Huntjens DR, Smith PF. Patel K, et al. Among authors: smith pf. J Antimicrob Chemother. 2019 Feb 1;74(2):442-452. doi: 10.1093/jac/dky415. J Antimicrob Chemother. 2019. PMID: 30376079 Clinical Trial.
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P, Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S. Forestier N, et al. Among authors: smith p. J Hepatol. 2011 Jun;54(6):1130-6. doi: 10.1016/j.jhep.2010.11.001. Epub 2011 Feb 24. J Hepatol. 2011. PMID: 21145848 Clinical Trial.
The effect of mild to moderate renal impairment on the pharmacokinetics of the nucleoside analog hepatitis C virus polymerase inhibitor mericitabine.
Haznedar J, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC. Haznedar J, et al. Among authors: smith w, smith p. Drug Dev Res. 2014 Mar;75(2):107-13. doi: 10.1002/ddr.21166. Epub 2013 Dec 26. Drug Dev Res. 2014. PMID: 24648253 Clinical Trial.
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team. Smith PF, et al. Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61. doi: 10.1128/AAC.49.8.3558-3561.2005. Antimicrob Agents Chemother. 2005. PMID: 16048984 Free PMC article. Clinical Trial.
12,909 results
You have reached the last available page of results. Please see the User Guide for more information.